| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/16/2006 | US20060057641 Having T cell stimulatory activity of a dog dander allergen, therapy |
| 03/16/2006 | US20060057582 83 human secreted proteins |
| 03/16/2006 | US20060057577 Diagnostics and therapeutics for diseases associated with homo sapiens formyl peptide receptor-like 2 |
| 03/16/2006 | US20060057573 Methods and reagents for detecting target binding by nucleic acid ligands |
| 03/16/2006 | US20060057570 Antisense modulation of hematopoietic cell protein tyrosine kinase expression |
| 03/16/2006 | US20060057220 Fine spherical particles with satisfactory molecular orientation, spherical microcapsules comprising the same and processes for producing these |
| 03/16/2006 | US20060057188 Dietary supplement energy-providing to skeletal muscles |
| 03/16/2006 | US20060057184 Process to treat avascular necrosis (AVN) with osteoinductive materials |
| 03/16/2006 | US20060057166 Methods for treating Raynaud's syndrome |
| 03/16/2006 | US20060057156 Materials and methods for inductions of immune tolerance |
| 03/16/2006 | US20060057155 Adp-ribosylating bacterial toxins |
| 03/16/2006 | US20060057154 Compositions for inducing of immunotolerance |
| 03/16/2006 | US20060057146 Selective targeting of tumor vasculature using antibody molecules |
| 03/16/2006 | US20060057145 Methods to prevent tumor recurrence by blockade of tgf-beta |
| 03/16/2006 | US20060057144 reducing IgG-mediated tissue damage and inflammation from rheumatoid arthritis; compound inhibits Fc.gamma.RIIa receptor binding of immunoglobulin; drug design; BRI6728, BRI6734, BRI6813, BRI6800, BRI6801, BRI6802, BRI6803, BRI6814, BRI6817, BRI6822, BRI6823, BRI6824, BRI6798, BRI6799, BRI6815, BRI6825 |
| 03/16/2006 | US20060057143 Diagnostics and therapeutics for diseases associated with chemokine receptor 11 (ccr11) |
| 03/16/2006 | US20060057141 Ovarian carcinoma polypeptides having a specific amino acid sequence, its fusion proteins and polynucleotides encoding them; cancer vaccines |
| 03/16/2006 | US20060057139 Process for producing humanized chimera antibody |
| 03/16/2006 | US20060057137 Glp-1 and methods for treating diabetes |
| 03/16/2006 | US20060057136 Immunotherapy of B-Cell malignancies using anti-CD22 antibodies |
| 03/16/2006 | US20060057133 Topical pathogenic-tissue-destroying liquid |
| 03/16/2006 | US20060057131 Malleable protein matrix and uses thereof |
| 03/16/2006 | US20060057123 Method of inducing memory B cell development and terminal differentiation |
| 03/16/2006 | US20060057117 Vascular endothelial growth factor 2 |
| 03/16/2006 | US20060057115 Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| 03/16/2006 | US20060057112 Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances and uses thereof |
| 03/16/2006 | US20060057111 Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
| 03/16/2006 | US20060057110 Antigen-presenting cells for neuroprotection and nerve regeneration |
| 03/16/2006 | US20060057107 Combination treatment for multiple sclerosis |
| 03/16/2006 | US20060057106 Freeze-dried interferon-y composition for transpulmonary administration and inhalation system therefor |
| 03/16/2006 | US20060057105 Methods of treating ocular inflammation and allergy |
| 03/16/2006 | US20060057104 Methods for stimulating tlr irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses |
| 03/16/2006 | US20060057103 A mutein of IL-15 at least one deletion or substitution in two positions of the amino acid sequence; transplant rejection, autoimmune diseases, inflammatory bowel disease, skin disorders, gatrointestinal disorders, vision defects; antiarthritic, anticarcinogenic, and antidiabetic agents |
| 03/16/2006 | US20060057102 Mutant interleukin-15-containing compositions and suppression of an immune response |
| 03/16/2006 | US20060057070 Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use |
| 03/16/2006 | US20060057067 inhibiting cerebrospinal fluid (CSF) production; repeatedly removing CSF from subarachnoid space and replacing CSF by infusing a lymph-like fluid composition into space; neuro-cardiopulmonary resuscitation; artificial CSF is polypeptides (gelatins), ionic magnesium (Mg2+), ATP, and insulin; mild acidosis |
| 03/16/2006 | US20060057065 Composition and method to prevent and treat brain and spinal cord injuries |
| 03/16/2006 | US20060057064 Useful in SPECT image diagnosis, PET image diagnosis, MRI image diagnosis and the like, for imaging sites of inflammation |
| 03/16/2006 | US20060057063 Therapy of cancer, diagnosis, imaging; drug conjugate; targeting agent and an anti-cancer agent, wherein targeting agent comprises an erythropoietin receptor ligand |
| 03/16/2006 | DE102005032094A1 Gemisch zur Verringerung von Blutfett Mixture to reduce blood fat |
| 03/16/2006 | DE102004041588A1 Dermatological composition, useful for reducing hair falls and/or promoting hair growth, comprises n-biotinyl-glycine-histidine-lysine, apigenin, oleanolic acid, ethanol, isopropanol, acid or base for adjusting the pH value and water |
| 03/16/2006 | DE102004035337A1 Varianten der Gruppe 1-Allergene aus Poaceae mit reduzierter Allergenität und erhaltener T-Zellreaktivität Variants of the group 1 allergens from Poaceae with reduced allergenicity and preserved T cell reactivity |
| 03/16/2006 | CA2579884A1 Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis |
| 03/16/2006 | CA2579775A1 Truncated lhrh formulations |
| 03/16/2006 | CA2579768A1 Enzyme inhibitors and uses thereof |
| 03/16/2006 | CA2579720A1 A pharmaceutical composition for treating ataxia, multiple system atrophy or balance disorders |
| 03/16/2006 | CA2579547A1 Novel peptides and methods for the treatment of inflammatory disease |
| 03/16/2006 | CA2579352A1 Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
| 03/16/2006 | CA2579038A1 Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| 03/16/2006 | CA2579030A1 Controlled and directed local delivery of anti-inflammatory compositions |
| 03/16/2006 | CA2578988A1 Phytases, nucleic acids encoding them and methods of making and using them |
| 03/16/2006 | CA2578748A1 Composition and method for prevention or treatment of stomatitis |
| 03/16/2006 | CA2578146A1 Improved apo e analogs and methods for their use |
| 03/16/2006 | CA2575753A1 Muteins of fibroblast growth factor 21 |
| 03/15/2006 | EP1634953A2 Platelet-activating factor acethylhydrolase |
| 03/15/2006 | EP1634951A1 Novel protein |
| 03/15/2006 | EP1634618A1 Method for identifying compounds that increase bone mineral density |
| 03/15/2006 | EP1634605A2 Treatment of dyslipidemia in a patient having type 2 diabetes |
| 03/15/2006 | EP1634604A1 Use of erythropoietin for treating liver diseases associated with iron overload |
| 03/15/2006 | EP1634603A1 Treatment of transformed or infected biologic Cells |
| 03/15/2006 | EP1634601A2 Dietary supplement comprising soyabean, mushroom and mung bean |
| 03/15/2006 | EP1634576A1 DNA repair enzymes and oligopeptides containing cosmetic and dermatological compositions |
| 03/15/2006 | EP1633883A1 Method for assaying lkb1 phosphorylation activity |
| 03/15/2006 | EP1633882A1 Diagnostics and therapeutics for diseases associated with puromycin-insensitive leucyl-specific aminopeptidase (pils) |
| 03/15/2006 | EP1633874A2 Method for producing glucoamylases and their uses |
| 03/15/2006 | EP1633872A2 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/15/2006 | EP1633866A1 New biological entities and the pharmaceutical or diagnostic use thereof |
| 03/15/2006 | EP1633865A1 New biological entities and the use thereof |
| 03/15/2006 | EP1633863A1 Ceramide kinase-like proteins |
| 03/15/2006 | EP1633783A2 Collagen fibrils carrying bioactive heterologous domains and their use in e.g. wound healing |
| 03/15/2006 | EP1633780A2 Control of lactation and peptides therefore |
| 03/15/2006 | EP1633778A1 Poly-gamma-glutamic acid conjugates for eliciting immune responses directed against bacilli |
| 03/15/2006 | EP1633774A1 Macrocyclic antagonists of the motilin receptor |
| 03/15/2006 | EP1633773A2 D-amino acid peptides |
| 03/15/2006 | EP1633769A1 Novel transcription factor, bp1 |
| 03/15/2006 | EP1633759A1 Cross-linked glycopeptide - cephalosporin antibiotics |
| 03/15/2006 | EP1633440A1 Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles |
| 03/15/2006 | EP1633394A1 Combined pharmaceutical preparations for the treatment of cancer, containing glutaminase and antineoplastic anthracyclines or platinum compounds |
| 03/15/2006 | EP1633393A1 Use of a clostridial toxin to reduce appetite |
| 03/15/2006 | EP1633392A2 Vector for oral administration |
| 03/15/2006 | EP1633391A1 Stabilized pharmaceutical peptide compositions |
| 03/15/2006 | EP1633390A2 Stabilized pharmaceutical peptide compositions |
| 03/15/2006 | EP1633389A1 Unitary combination of fsh and hcg |
| 03/15/2006 | EP1633388A2 Liquid stabilized protein formulations in coated pharmaceutical containers |
| 03/15/2006 | EP1633386A1 Pharmaceutical composition for inducing apoptosis comprising a fusion protein between bfl-1 and green fluorescent protein or a gene encoding same |
| 03/15/2006 | EP1633385A1 Compositions and methods for treatment of rosacea |
| 03/15/2006 | EP1633384A2 Stable analogs of peptide and polypeptide therapeutics |
| 03/15/2006 | EP1633383A2 Use of erythropoietin in stroke recovery |
| 03/15/2006 | EP1633382A2 Repeat sequence protein polymer active agent conjugates, methods and uses |
| 03/15/2006 | EP1633381A2 Assays using amyloid precursor proteins with modified beta-secretase cleavage sites to monitor beta-secretase activity |
| 03/15/2006 | EP1633380A2 Antimicrobial and anticancer lipopeptides |
| 03/15/2006 | EP1633317A2 Synthetic chemokine receptor ligands and methods of use thereof |
| 03/15/2006 | EP1633315A2 Novel immunomodulating peptide |
| 03/15/2006 | EP1633311A2 Compositions and methods for modulating s-nitrosoglutathione reductase |
| 03/15/2006 | EP1633305A2 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window |
| 03/15/2006 | EP1633304A2 Vascular endothelial growth factor fusion constructs and uses thereof |
| 03/15/2006 | EP1633302A2 Modulation of apolipoprotein (a) expression |
| 03/15/2006 | EP1509206A4 A hemostatic composition |
| 03/15/2006 | EP1470155B1 Pluripotency determining factor and uses thereof |
| 03/15/2006 | EP1451577A4 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases |